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Evidence suggests that neurohormones such as GH and IGF-I are involved in the neuroreparative processes in multiple sclerosis
(MS). GH and IGF-I blood levels in naı¨ve MS patients with different disease courses were investigated in this study. Serum GH
and IGF-I in untreated MS patients (𝑛 = 64), healthy controls (HC, 𝑛 = 62), and patients affected by other neurological diseases
(OND, 𝑛 = 46) were evaluated with a solid-phase-enzyme-labeled-chemiluminescent-immunometric assay. No differences were
detected in GH across MS, OND, and HC (MS = 0.87 ± 1.32 ng/mL; OND = 1.66 ± 3.7; and HC = 1.69 ± 3.35; 𝑃 = 0.858) when
considering gender, disease duration, and disease course. However, GH was lower (𝑃 = 0.007) in patients with more severe disease
(expanded disability scale score, EDSS ≥ 4.0) compared with milder forms (EDSS < 4). IGF-I l did not differ across the 3 groups
(𝑃 = 0.160), as far as concern disease course, disability, and gender were. Lower IGF-I levels were detected in subjects older than 50
years compared to younger ones for all 3 groups. Lower GH was detected in patients with more severe MS, and age was confirmed
as the main factor driving IGF-I levels in all subjects. These findings, relying on the natural course of the disease, could help in
shedding lights on the mechanisms involved in autoreparative failure associated with poorer prognosis in MS.
1. Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease
of the central nervous system with an unpredictable time
course. Among the plethora of factors affecting the clinical
heterogeneity of MS, autoreparative mechanisms are of par-
ticular importance. Remyelination is largely known to occur
in MS [1], but it is still unclear why its adequacy differs so
largely among patients. Many factors have been proposed
to influence remyelination, including several neuroendocrine
factors [2, 3]. Unresponsiveness to these factors and/or their
insufficient release could possibly be involved in reparative
mechanism failure, and studies focusing on these molecules
have attracted a great deal of attention.
Growth hormone and IGF-I have been recognised as
factors that can affect survival of myelin and central nervous
system (CNS) cells [3, 4]. Several studies [2–4] have focused
on these growth factors, unfortunately with equivocal results.
Heterogeneity is not largely dependent on the different
methodologies used but also on the disease’s natural history.
Growth factor bioavailability can vary in the different phases
of the disease leading to a permissive or, on the contrary,
an inadequate microenvironment supporting remyelination.
Moreover, another putative confounding factor could be
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Table 1: Demographic and clinical characteristics of the MS, OND patients, OND and HC.
MS (𝑛 = 64) OND (𝑛 = 46) HC (𝑛 = 62) 𝑃
Age (mean ± SD) 50.21 ± 8.08 48.48 ± 15.41 48.87 ± 7.14 0.640
Male : female 27 : 37 20 : 26 23 : 39 0.786
EDSS (mean ± SD) 4.57 ± 2.17 — — —
PP (𝑛) 19 — — —
SP (𝑛) 23 — — —
RR (𝑛) 22 — — —
RR: relapsing-remitting; SP: secondary progressive; PP: primary progressive, EDSS: expanded disability scale score.
the different treatments known to influence neurohormone
secretion (e.g., glucocorticoids).
The aim of the present study was to investigate GH
and IGF-I blood levels in a population of treatment na¨ıve
MS patients at different phases of the disease. Two different
control groups were used, namely, healthy control (HC)
subjects and other neurological disease (OND) patients.
2. Materials and Methods
2.1. Subjects. Sixty-four therapy-na¨ıve MS patients, 46 age-
matched subjects affected by OND, and 62 healthy controls
HCwere recruited as outpatients from June 2009 to June 2011
at S. Maria Nascente, Fondazione Don C. Gnocchi (Milan
Italy), at Ospedale S. Antonio Abate (Gallarate, VA Italy),
at Ospedale Micone (Genova Italy), and at the Department
of Neuroscience of Cattolica University (Rome Italy). The
study protocol was approved by the local Ethics Commit-
tees of the respective institutions in accordance with the
Declaration of Helsinki (1964). Eligible subjects signed a
written informed consensus.MSpatients satisfied the Polman
criteria [5] and were in a clinically stable phase for at least
two months earlier and not treated with immunomodulatory
or immunosuppressive drugs. The OND group included
patients affected by chronic neurological diseases different
from demyelinating disorders (posttraumatic haemorrhage,
stroke, mild cognitive impairment, and headache). Exclu-
sion criteria included treatment with steroids, 𝛽-blockers,
selective serotonin reuptake inhibitors (SSRI), and benzodi-
azepines (known to influence GH and IGF-I levels).
Disease course was classified as relapsing-remitting (RR:
𝑛 = 22), secondary progressive (SP: 𝑛 = 23), or primary
progressive (PP: 𝑛 = 19). All MS patients were evaluated with
the expanded disability severity scale (EDSS). Subjects were
matched for age and sex (𝑃 = 0.786; 𝑃 = 0.640, Table 1).
Blood samples were collected in the morning (8 am–
10 am) in a fasting state and delivered to the central laboratory
of the IRCCS SanMatteo Foundation, within 12 hours. Serum
samples were obtained by centrifugation and stored at −20∘C
until assays could be performed.
2.2. Immunometric Assays. Serum GH and IGF-I were
assayed with a fully automated immunochemistry analyser,
immulite 2000 (Siemens Diagnostics). Methods for assaying
GH and IGF-I were based on a solid phase, two-site immuno-
metric sandwich assay with a chemiluminescent signal. The
method for GH assay is characterized by an analytical
sensitivity of 0.01 ng/mL and a linearity range (reportable
range) from 0.05 to 40 ng/mL. The intra- and interassay
coefficients of variation for GH were 5.3%–6.5% and 5.7%–
6.1% for a quality control range of 1.7–31 ng/mL and 3.0–
18 ng/mL, respectively. The intra- and inter-assay coefficients
of variation for IGF-I were 3.9%–2.4% and 5.1%–4.8% for a
quality control range of 77–1,358 ng/mL, respectively.
2.3. Statistical Analysis. All statistical analyses were per-
formed using the statistical package for the Social Sci-
ences (SPSS), version 15.0, for Windows (SPSS, Chicago, IL,
USA).The normality of the distribution for all variables was
assessed by theKolmogorov-Smirnov test.TheStudent’s 𝑡-test
and ANOVA were used for normally distributed variables.
Neither serum GH nor IGF-I blood levels were normally
distributed as evidenced with the Kolmogorov-Smirnov test
(serum GH: 𝑃 = 0.000; serum IGF-I: 𝑃 = 0.043).
Accordingly, for both GH and IGF-I, differences between
two groups were assessed with the Mann-Whitney 𝑈 test.
Differences between more than two groups were assessed
with the Kruskal-Wallis test. A 𝑃 value <0.05 was considered
statistically significant.
3. Results
The characteristics of MS patients, OND, and the HC group
are summarized in Table 1.
IGF-I did not significantly differ in MS compared with
HC and OND subjects (𝑃 = 0.160, Table 2). No group
differences were associated with different disease courses
neither for GH (PP = 0.96 ± 1.71 ng/mL; SP = 0.88 ±
1.26 ng/mL; and RR = 0.79 ± 1.05 ng/mL; and 𝑃 = 0.662)
nor for IGF-I (PP = 161.86 ± 62.66 ng/mL; SP = 135.23 ±
47.82 ng/mL; and RR = 163.44 ± 53.98 ng/mL; 𝑃 = 0.182).
Moreover, as far as gender was concerned, significantly
higher levels of GH were detected in females compared with
males for MS, OND, and HC groups (Table 2). A trend in
lower levels of GH in female MS patients compared with
female OND and HC subjects was also observed (Table 2).
For all studied groups (MS, OND, and HC), IGF-I
was lower in older subjects (≥50 years) compared with
younger subjects (<50 years) (Table 2). No such difference
was detected for GH levels (Table 2).
Importantly, we also investigated a possible relationship
between GH and IGF-I levels and severity of disease. We
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Figure 1: Serum GH levels in MS patients according to disease
duration and EDSS score. Values are expressed as mean ± SD; ∗𝑃 <
0.05 (nonparametric test Mann-Whitney 𝑈).
considered 500 meter walking autonomy (scored EDSS = 4),
a clinically significant progression marker. Accordingly, MS
patients were stratified into different groups. Group A: EDSS
≥ 4 within the first 10 years of disease; group B: EDSS < 4
within the first 10 years of disease; group C: EDSS ≥ 4 with
disease duration longer than 10 years; and group D: EDSS <
4 with disease duration longer than 10 years.
Lower GH levels were detected in patients with EDSS ≥
4 within the first 10 years of the disease compared to patients
with EDSS < 4 within the first 10 years of the disease (group
A: 0.18 ± 0.15 ng/mL; group B: 1.39 ± 1.39 ng/mL; 𝑃 =
0.007, Figure 1). The number of females in group B was not
significantly different from the number of females in group A
(𝜒2 = 2.48; 𝑃 = 0.115).
Interestingly, there were no differences for longer disease
duration (more than 10 years) (group C: 0.85±1.38; group D:
0.76 ± 1.32 ng/mL; 𝑃 = 0.558, Figure 1).
Considering IGF-I, no differences were found when
comparing patients stratified according to the same criteria
of disease duration and MS severity (data not shown).
4. Discussion
The phenomenon of remyelination is regulated by several
mechanisms and influenced by the bioavailability of many
molecules. Much attention has been focused on growth
factors, such as GH and IGF-I, which are well known to pos-
itively affect remyelination. IGF-I is a potent neuroprotective
factor for neurons and oligodendrocytes [3, 6] involved in
oligodendrocyte precursor cell (OPC) proliferation and dif-
ferentiation [1] and in myelin synthesis [3, 6]. Its secretion is
induced by GH which is a neuroprotective molecule itself for
adult myelin maintenance and endowed with antiapoptotic
effects [4]. Shedding light on their roles in vivo could prove
to be noteworthy, since these growth factors are now available
as substitutive therapy [7] to be tailored to the peculiar need
of an individual disease.
Our study did not detect any significant differences
concerning GH and IGF-I levels inMS patients. Interestingly,
however, we found lower GH levels in MS patients with a
higher disability score (EDSS ≥ 4.0) during the first 10 years
of disease than in patients with a milder disease course (no
walking limitations). Importantly, this difference is present
within the first 10 years of the disease, but it disappears after
this timewindow.Webelieve these findings are interesting for
several reasons. First, remyelination has been shown to occur
over the entire disease course, but the phenomenon is most
evident during the first years of disease [1]. It is reasonable
to postulate that when myelin and oligodendroglial turnover
increase, as it happens in the early phase of MS, GH may
positively modulate repair mechanisms. It is also possible to
speculate that carrying a higher level of GH during this early
phase might therefore confer protection to OPC survival,
establishing a more favourable disease course. Secondly, the
lack of difference in serum IGF-I, according to the same
stratification criteria, strengthens the role of GH as a neuro-
protective factor itself [4], not just amediator of IGF-I release.
Thirdly, MS patients were all untreated; thus, confounding
factors due to immune-modulatory (suppressive) treatment
can reasonably be excluded. Accordingly, the results of the
present study cannot be linked to different dosages or types of
therapy inmore disabled patients but crucially rely on natural
mechanisms of the disease.
Another noteworthy finding is the detection of lower
levels of IGF-I in patients older than 50 years. We confirmed
the well-known [8] inverse correlation between age and IGF-
I. Importantly, such a correlation was observed even in MS
patients. It is conceivable that lower levels of IGF-I may
hinder reparative processes. According to this hypothesis, the
resulting inefficiency in reparative processes could enhance
disease progression in older patients and would explain the
worse prognosis reported in the literature associated with late
disease onset [9].
Although not statistically significant, we have shown
lower GH levels in MS females compared with control and
OND females. Females are well known to be GH resistant
and have higher GH serum levels than males [10]. This
gender difference was observed also in MS patients, but
between males and females MS, the difference was weaker
than that shown for OND or HC. Female-GH resistance,
when not overcome by higher GH level (as in healthy and
OND females), might be speculated as one of the factors
involved in female-MS prevalence [11].
The main drawback of our study was the small number
of patients enrolled in each disease class. This would also
explain the lack of statistical significance reported. In addi-
tion, several other factors can explain our results, indirectly
modulating the GH/IGF-I axis. For example, the role of IGF
binding proteins (IGFBPs) has been investigated, as these
proteins are primarily responsible for transport of IGF-I [3] to
target tissues, and they play an inhibitory role in IGF-I-driven
myelination.
Recently, Lanzillo and colleagues [2] did not find a
difference in IGF-I per se between HC and MS but detected
a lower IGF-I/IGFBP-3 ratio in MS compared with controls.
Interestingly, higher levels of IGFBP-3 in more disabled
patients (with higher EDSS at 10 years of disease) were
found, suggesting the reduced bioavailability of IGF-I (more
than a lower IGF-I level) as a possible pathogenetic factor.
Although our study was not designed to investigate IGF-I
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bioavailability, hence; we did not measure IGFBP, our results
could be in agreement with those of the authors. The lack
of different values for IGF-I in higher EDSS patients, as we
disclosed for GH, could be associated with higher IGFBP
(lower bioavailability). Unlike GH, IGF-I bioavailabilitymore
than IGF-I level might be relevant to MS susceptibility.
5. Conclusions
In conclusion, we reported a lower level of GH for higher
cumulative disability and lower IGF-I for older patients.
Notwithstanding several biases of the study (no cerebrospinal
fluid analyses available, relatively small groups), our findings
are noteworthy because they correlate with the natural course
of the disease (not biased by treatment confounding factors).
They sound to suggest that blood GH and IGF-I levels
should not be considered as biomarkers of disease, but rather
prognostic biomarkers. These findings should encourage
larger studies to dissect further the involvement of GH and
IGF-I in MS mechanisms.
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